Therefore, we propose that rosmarinic acid is a good starting point for developing a new type of inhibitors for the treatment of non-small-cell lung cancer with drug-resistant EGFR and rheumatoid arthritis. Here, EGFR is linked to non-small cell lung carcinoma.